Erianin Potentiates the Efficacy of Immune Checkpoint inhibitor in Cholangiocarcinoma by Inhibiting FAK-mediated cell growth and senolytic activity

Objective: Cholangiocarcinoma (CCA) is a highly aggressive malignancy with limited therapeutic options and poor prognosis. Erianin has demonstrated broad-spectrum antitumor activity, yet its role in CCA and tumor immunity remains unclear. Methods: The